AcuTect Phase IV Study Will Examine Utility Of Negative Thrombosis Scans
This article was originally published in The Gray Sheet
Executive Summary
The clinical utility of a negative test result in the imaging of venous thrombosis will be examined in a post-approval study of Diatide's AcuTect. The apcitide technetium Tc 99m kit was approved by FDA Sept. 14.
You may also be interested in...
Schering Entering Radiopharmaceuticals Market Via $128 Mil. Diatide Deal
Schering AG is looking to accelerate its expansion into the worldwide radiopharmaceuticals market through the acquisition of Diatide. The $128 mil. cash deal was announced Sept. 20.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.